Tobin W. Juvenal Sells 3,507 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin W. Juvenal sold 3,507 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the transaction, the insider now directly owns 54,178 shares in the company, valued at $1,926,569.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Castle Biosciences Stock Performance

NASDAQ:CSTL traded up $0.65 on Thursday, hitting $33.31. The stock had a trading volume of 385,114 shares, compared to its average volume of 324,657. The stock has a market cap of $919.69 million, a price-to-earnings ratio of 168.06 and a beta of 0.99. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02. The business’s 50-day simple moving average is $30.78 and its two-hundred day simple moving average is $25.72. Castle Biosciences, Inc. has a 52-week low of $16.20 and a 52-week high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.50% and a net margin of 1.95%. The firm had revenue of $85.78 million for the quarter, compared to analysts’ expectations of $78.55 million. During the same period in the previous year, the firm earned ($0.26) EPS. As a group, research analysts predict that Castle Biosciences, Inc. will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors have recently bought and sold shares of the business. Quest Partners LLC raised its position in shares of Castle Biosciences by 54.4% during the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after buying an additional 1,522 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Castle Biosciences by 58.0% during the third quarter. Thrivent Financial for Lutherans now owns 23,290 shares of the company’s stock valued at $664,000 after purchasing an additional 8,552 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Castle Biosciences in the 3rd quarter valued at approximately $1,478,000. Lisanti Capital Growth LLC boosted its holdings in shares of Castle Biosciences by 60.2% in the 3rd quarter. Lisanti Capital Growth LLC now owns 154,710 shares of the company’s stock worth $4,412,000 after purchasing an additional 58,160 shares during the period. Finally, Assetmark Inc. increased its position in shares of Castle Biosciences by 16.8% during the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after purchasing an additional 748 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

CSTL has been the topic of a number of research reports. BTIG Research boosted their price objective on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Scotiabank boosted their price objective on Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday. Lake Street Capital upped their price target on Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Robert W. Baird upped their price target on Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, KeyCorp upped their price target on Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a research report on Tuesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $37.88.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.